Generex Biotechnology to Present Clinical Trial Results at the Fifth Annual Diabetes Technology Meeting
Tuesday November 8, 4:00 pm ET
TORONTO--(MARKET WIRE)--Nov 8, 2005 -- Generex Biotechnology Corporation (NasdaqSC:GNBT - News), a leader in the area of buccal drug delivery, today announced that clinical trial results in respect of Oral-lyn(TM), its proprietary oral insulin spray product, will be presented at the Fifth Annual Diabetes Technology Meeting to be held in San Francisco from November 10 - 12, 2005. The following poster presentations will be made on Thursday, November 10, 2005:
-- "A 12-Day Comparison of Preprandial Humulin® vs. Oral-lyn(TM) in 10
Type 1 Diabetic Subjects Receiving Baseline Glargine Insulin Therapy," a
study coauthored by Dr. Jaime Guevara-Aguirre, Marco Guevara, and Jeannette
Saavedra, all of the Institute of Endocrinology IEMYR in Quito, Ecuador;
and
-- "Addition of Oral-lyn(TM) at Mealtimes in Subjects with Type 2
Diabetes Maintained on Glargine + Metformin - A Comparison with Placebo," a
study coauthored by Professor Itamar Raz of Hadassah Hospital, Jerusalem,
Israel together with M. Kidron (also of Hadassah Hospital) and M. Dubinsky
and J. Wainstein of Wolfson Hospital, Holon, Israel.
ADVERTISEMENT
The Meeting's goal is to assemble technology developers and users to facilities creation of new and cost-effective tools to help people with diabetes. The Meeting will place particular emphasis on original data. |
